ADRB2 and Parkinson disease: It has been suggested that the use of β2AR agonists in PD patients has been evaluated only in small open-label studies, detecting a reduction in Parkinsonian symptoms and daily levodopa dose [124], increased duration of daily total ON [125], and response to Levodopa [126].